Clinical Scorecard: A New Marker of Multiple Sclerosis Progression?

At a Glance

Key Highlights

• Foamy microglia associated with faster disease progression.
• Chronic lesions can expand and damage nerve tissue.
• Monoacylglycerol lipase (MAGL) identified as a potential therapeutic target.
• Lipid molecules (oxylipins) may serve as biomarkers for chronic lesion activity.
• Study emphasizes the importance of histopathology and molecular profiling.

Guideline-Based Recommendations

Diagnosis

• Further studies needed to confirm the clinical value of identified biomarkers.

Management

• Limited treatment options for progressive MS; focus on understanding chronic lesions.

Monitoring & Follow-up

• Identifying lipid-filled microglia could improve monitoring of chronic active lesions.

Risks

• Patients with more foamy lesions reached disability milestones sooner.

Patient & Prescribing Data

Patients with secondary progressive multiple sclerosis.

Current disease-modifying therapies primarily reduce relapses in early MS.

Clinical Best Practices

• Combine histopathology with molecular profiling for better understanding of progressive MS.

Related Resources & Content

• Nature Neuroscience